BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) expression is increased in epithelial cancer patients, but studies showing its relation to prognosis are scarce. We aimed to test the ability of preoperative serum NGAL levels (pNGAL) to predict recurrence in metastatic and nonmetastatic colorectal cancer (CRC) patients. METHODS: This retrospective study determined pNGAL levels in 60 healthy individuals, 47 patients with nonmetastatic CRC, and 70 patients with metastatic CRC undergoing curative neoplastic resection. Patients were divided into low- and high-pNGAL groups using a median series-based cutoff. RESULTS: The mean ± SD pNGAL in CRC patients (nonmetastatic and metastatic) was 102.3 ± 66.6 (median 91.4). Nonmetastatic CRC and metastatic CRC patients had higher pNGAL than healthy controls (88 ± 64 and 112 ± 67 vs. 0.6 ± 0.3, respectively, both p < 0.0001). Nonmetastatic CRC patients with deeper tumor invasion and metastatic CRC patients with shorter disease-free interval after CRC resection had higher pNGAL. pNGAL levels correlated with neoplastic tissue volume. CRC patients with recurrence had higher pNGAL than those without recurrence (118 ± 64 vs. 88 ± 66, p = 0.013), and high-pNGAL patients had a higher recurrence rate (59.3 vs. 36.2 %, p = 0.016). Median pNGAL-based risk classification had a sensitivity of 62.5 % for predicting neoplastic progression in CRC patients and 74.3 % for predicting neoplastic progression during the first year after metastatic CRC resection. CONCLUSIONS: pNGAL is higher in CRC patients than in the healthy population, which indicates a potential screening role. High-pNGAL levels are associated with higher neoplastic tissue volume, characteristics of neoplastic invasion, and recurrence, showing a prognostic utility mainly in metastatic CRC patients.
BACKGROUND:Neutrophil gelatinase-associated lipocalin (NGAL) expression is increased in epithelial cancerpatients, but studies showing its relation to prognosis are scarce. We aimed to test the ability of preoperative serum NGAL levels (pNGAL) to predict recurrence in metastatic and nonmetastatic colorectal cancer (CRC) patients. METHODS: This retrospective study determined pNGAL levels in 60 healthy individuals, 47 patients with nonmetastatic CRC, and 70 patients with metastatic CRC undergoing curative neoplastic resection. Patients were divided into low- and high-pNGAL groups using a median series-based cutoff. RESULTS: The mean ± SD pNGAL in CRCpatients (nonmetastatic and metastatic) was 102.3 ± 66.6 (median 91.4). Nonmetastatic CRC and metastatic CRCpatients had higher pNGAL than healthy controls (88 ± 64 and 112 ± 67 vs. 0.6 ± 0.3, respectively, both p < 0.0001). Nonmetastatic CRCpatients with deeper tumor invasion and metastatic CRCpatients with shorter disease-free interval after CRC resection had higher pNGAL. pNGAL levels correlated with neoplastic tissue volume. CRCpatients with recurrence had higher pNGAL than those without recurrence (118 ± 64 vs. 88 ± 66, p = 0.013), and high-pNGAL patients had a higher recurrence rate (59.3 vs. 36.2 %, p = 0.016). Median pNGAL-based risk classification had a sensitivity of 62.5 % for predicting neoplastic progression in CRCpatients and 74.3 % for predicting neoplastic progression during the first year after metastatic CRC resection. CONCLUSIONS: pNGAL is higher in CRCpatients than in the healthy population, which indicates a potential screening role. High-pNGAL levels are associated with higher neoplastic tissue volume, characteristics of neoplastic invasion, and recurrence, showing a prognostic utility mainly in metastatic CRCpatients.
Authors: Josep Martí; María Marta Modolo; Josep Fuster; Jaume Comas; Rebeca Cosa; Joana Ferrer; Victor Molina; Juan Romero; Constantino Fondevila; Ramón Charco; Juan Carlos García-Valdecasas Journal: World J Gastroenterol Date: 2009-06-07 Impact factor: 5.742
Authors: L Landrø; J K Damås; T H Flo; L Heggelund; T Ueland; G E Tjønnfjord; T Espevik; P Aukrust; S S Frøland Journal: Clin Exp Immunol Date: 2008-01-28 Impact factor: 4.330
Authors: Davide Bolignano; Valentina Donato; Antonio Lacquaniti; Maria Rosaria Fazio; Caterina Bono; Giuseppe Coppolino; Michele Buemi Journal: Cancer Lett Date: 2009-06-18 Impact factor: 8.679
Authors: Herbert Thomas Maier; Felix Aigner; Birgit Trenkwalder; Matthias Zitt; Natalie Vallant; Alexander Perathoner; Christian Margreiter; Patrizia Moser; Johann Pratschke; Albert Amberger Journal: World J Surg Date: 2014-08 Impact factor: 3.352
Authors: Mehmet Odabasi; Atakan Yesil; Selvinaz Ozkara; Nurcan Paker; Sevil Ozkan; Cengiz Eris; Mehmet Kamil Yildiz; Hacı Hasan Abuoglu; Emre Gunay; Kemal Tekeşin Journal: Int J Clin Exp Med Date: 2014-09-15
Authors: Sukhwinder Kaur; Neil Sharma; Shiv Ram Krishn; Imay Lakshmanan; Satyanarayana Rachagani; Michael J Baine; Lynette M Smith; Subodh M Lele; Aaron R Sasson; Sushovan Guha; Kavita Mallya; Judy M Anderson; Michael A Hollingsworth; Surinder K Batra Journal: Clin Cancer Res Date: 2013-11-15 Impact factor: 12.531
Authors: Saverio Candido; Roberta Maestro; Jerry Polesel; Alessia Catania; Francesca Maira; Santo S Signorelli; James A McCubrey; Massimo Libra Journal: Oncotarget Date: 2014-03-30